title: SETDB1 is a new promising target in HCC therapy.
authors.affiliation: Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Department of Cellular Biotechnologies and Haematology, Sapienza University of Rome, Rome, Italy.
authors.forename: Carla
authors.initials: C
authors.lastname: Cicchini
authors.affiliation: Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Department of Cellular Biotechnologies and Haematology, Sapienza University of Rome, Rome, Italy.
authors.forename: Cecilia
authors.initials: C
authors.lastname: Battistelli
authors.affiliation: Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Department of Cellular Biotechnologies and Haematology, Sapienza University of Rome, Rome, Italy. tripodi@bce.uniroma1.it.
authors.forename: Marco
authors.initials: M
authors.lastname: Tripodi
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000235:genetics* / Q000473:pathology; D011495:Histone-Lysine N-Methyltransferase; D006801:Humans; D008113:Liver Neoplasms / Q000235:genetics* / Q000473:pathology; D011496:Protein Methyltransferases / Q000235:genetics*
chemical_list: D011496:Protein Methyltransferases; D011495:Histone-Lysine N-Methyltransferase; C454062:SETDB1 protein, human